Table 2.
Baseline eGFR, overall kidney function decline and incidence of adverse clinical outcomes, presented per subgroup
| Entire cohort (N = 1326) | Men (N = 883) | Women (N = 443) | ||||
|---|---|---|---|---|---|---|
| Outcome | No depressive symptoms (N = 811) | Depressive symptoms (N = 515) | No depressive symptoms (N = 588) | Depressive symptoms (N = 295) | No depressive symptoms (N = 223) | Depressive symptoms (N = 220) |
| Baseline eGFR ± SDa (mL/min/1.73 m2) | 18.95 ± 5.21 | 18.58 ± 5.78 | 18.83 ± 5.21 | 18.27 ± 5.59 | 19.26 ± 5.21 | 18.98 ± 6.01 |
| Overall kidney function decline (95% CI)b (mL/min/1.73 m2/month) | –0.14 (–0.16 to –0.11)** | –0.09 (–0.12 to –0.06)** | –0.16 (–0.19 to –0.14)** | –0.11 (–0.15 to –0.07)** | –0.07 (–0.12 to –0.03)* | –0.07 (–0.12 to –0.02)* |
| Start of dialysisc, N (%) | 237 (29.2) | 142 (27.6) | 189 (32.1) | 95 (32.2) | 48 (21.5) | 47 (21.4) |
| All-cause mortalityd, N (%) | 151 (18.6) | 121 (23.5) | 109 (18.5) | 75 (25.4) | 42 (18.8) | 46 (20.9) |
| Combined adverse outcomee, N (%) | 388 (47.8) | 263 (51.1) | 298 (50.7) | 170 (57.6) | 90 (40.4) | 93 (42.3) |
a
Estimated GFR—estimated glomerular filtration rate at baseline, calculated with the MDRD formula.
b
Overall decline in kidney function, calculated by Linear Mixed Modelling.
c
Number of patients that started dialysis during follow-up.
d
Number of patients that died during follow-up.
e
Number of patients that either started dialysis or died during follow-up.
*P < 0.05, **P < 0.01.